These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27545320)

  • 1. Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects.
    Morcos PN; Guerini E; Parrott N; Dall G; Blotner S; Bogman K; Sturm C; Balas B; Martin-Facklam M; Phipps A
    Clin Pharmacol Drug Dev; 2017 Jul; 6(4):388-397. PubMed ID: 27545320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy Subjects.
    Morcos PN; Parrott N; Banken L; Timpe C; Lindenberg M; Guerini E; Dall G; Bogman K; Sturm C; Zeaiter A; Martin-Facklam M; Phipps A
    Clin Pharmacol Drug Dev; 2017 May; 6(3):266-279. PubMed ID: 27545871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib.
    Morcos PN; Cleary Y; Guerini E; Dall G; Bogman K; De Petris L; Viteri S; Bordogna W; Yu L; Martin-Facklam M; Phipps A
    Clin Pharmacol Drug Dev; 2017 May; 6(3):280-291. PubMed ID: 27545757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib.
    Morcos PN; Cleary Y; Sturm-Pellanda C; Guerini E; Abt M; Donzelli M; Vazvaei F; Balas B; Parrott N; Yu L
    J Clin Pharmacol; 2018 Dec; 58(12):1618-1628. PubMed ID: 30052269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects.
    Morcos PN; Yu L; Bogman K; Sato M; Katsuki H; Kawashima K; Moore DJ; Whayman M; Nieforth K; Heinig K; Guerini E; Muri D; Martin-Facklam M; Phipps A
    Xenobiotica; 2017 Mar; 47(3):217-229. PubMed ID: 27180975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.
    Lau YY; Gu W; Lin T; Viraswami-Appanna K; Cai C; Scott JW; Shi M
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1119-1128. PubMed ID: 28424965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial.
    Fukano R; Mori T; Sekimizu M; Choi I; Kada A; Saito AM; Asada R; Takeuchi K; Terauchi T; Tateishi U; Horibe K; Nagai H
    Cancer Sci; 2020 Dec; 111(12):4540-4547. PubMed ID: 33010107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
    Choi Y; Han H; Shin D; Lim KS; Yu KS
    Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically Based Absorption Modeling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Alectinib.
    Parrott NJ; Yu LJ; Takano R; Nakamura M; Morcos PN
    AAPS J; 2016 Nov; 18(6):1464-1474. PubMed ID: 27450228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative bioavailability and food effect study of an oral suspension of alectinib in healthy volunteers using venipuncture and capillary microsampling.
    Liu SN; Agarwal P; Heinig K; Datye A; Sturm-Pellanda C; Crugnola A; Arca M; Miles D
    Clin Transl Sci; 2023 Jun; 16(6):1085-1096. PubMed ID: 36978270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
    Tugnait M; Gupta N; Hanley MJ; Venkatakrishnan K; Sonnichsen D; Kerstein D; Dorer DJ; Narasimhan N
    Clin Pharmacol Drug Dev; 2019 Aug; 8(6):734-741. PubMed ID: 30570839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
    Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
    Ito K; Hataji O; Kobayashi H; Fujiwara A; Yoshida M; D'Alessandro-Gabazza CN; Itani H; Tanigawa M; Ikeda T; Fujiwara K; Fujimoto H; Kobayashi T; Gabazza EC; Taguchi O; Yamamoto N
    J Thorac Oncol; 2017 Feb; 12(2):390-396. PubMed ID: 27498387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
    Kodama T; Hasegawa M; Takanashi K; Sakurai Y; Kondoh O; Sakamoto H
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1023-8. PubMed ID: 25205428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Efficacy of Alectinib in Patients with
    Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
    Anticancer Res; 2017 Nov; 37(11):6477-6480. PubMed ID: 29061835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioanalysis of alectinib and metabolite M4 in human plasma, cross-validation and impact on PK assessment.
    Heinig K; Miya K; Kamei T; Guerini E; Fraier D; Yu L; Bansal S; Morcos PN
    Bioanalysis; 2016 Jul; 8(14):1465-79. PubMed ID: 27329641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects.
    Nguyen L; Holland J; Mamelok R; Laberge MK; Grenier J; Swearingen D; Armas D; Lacy S
    J Clin Pharmacol; 2015 Nov; 55(11):1293-302. PubMed ID: 25907407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Food (Low and High Fat) on Pharmacokinetics of FCN-159, a Selective MEK Inhibitor, in Healthy Chinese Males.
    Li J; Tan Y; Li K; Hui AM; Wu Z; Han P; Wei Z; Qiu J; Diao L; Wang X
    Adv Ther; 2023 Mar; 40(3):1074-1086. PubMed ID: 36627544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.
    Cleary Y; Gertz M; Morcos PN; Yu L; Youdim K; Phipps A; Fowler S; Parrott N
    Clin Pharmacol Ther; 2018 Sep; 104(3):505-514. PubMed ID: 29226313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.